Journal rankings · indicator year 2025
Choose a field to open its ranking, or a journal to find its row in its subfield’s list.
Subfield ranking · 2025
Oncology journal rankings 2025
242 ranked journals · Subfield in Medicine
Oncology has 242 ranked journals in 2025. The median journal has an OJR of 0.75, below the world average of 1.00, up 0.02 on 2024; Q1 starts at OJR 1.19. The two highest-scoring journals with stable ranks are CA A Cancer Journal for Clinicians and Nature Medicine: each is likely ranked within the top 3.
Ranks and citation indicators: 2025. Journal access status and listed APC: source snapshot September 23, 2026.
Journals whose main subfield sits in this category and that published at least 30 citable documents (articles, reviews and conference papers) in 2022–2024, the window the 2025 score is computed on.
The OpenJournalRank Indicator (OJR) is a free, publicly available metric of a journal’s field-normalized citation impact, computed from open OpenAlex citation data. It compares citations to a journal’s papers from the previous three years with the world average for papers of the same subfield, year and type, so 1.00 is the world average and values can be compared across fields. It is computed with the NCI3 method.
The middle OJR among ranked journals in this category: half score higher, half lower. 1.00 is the world average for papers of the same subfield, year and type.
The dot is this category, the solid tick is the median of all ranked journals and the dashed line is the world average.
Share of ranked journals in this category that are fully open access, so every paper is free to read. Hybrid journals, which sell subscriptions and open single papers for a fee, are not counted.
Median list price of the article processing charge, in US dollars, among ranked journals in this category that list a price above zero. Journals with a listed APC of $0 and journals with no known price are left out of this median. The At a glance table below gives a second median that includes the $0 prices.
Subfields of Medicine (42)
- Surgery945
- Pulmonary and Respiratory Medicine352
- Public Health, Environmental and Occupational Health311
- Cardiology and Cardiovascular Medicine287
- Infectious Diseases258
- Oncology242
- Epidemiology178
- Neurology168
- Radiology, Nuclear Medicine and Imaging160
- Physiology154
- Endocrinology, Diabetes and Metabolism152
- Psychiatry and Mental health139
Show all 42 subfields
- Orthopedics and Sports Medicine121
- Ophthalmology96
- Pediatrics, Perinatology and Child Health95
- Dermatology89
- Obstetrics and Gynecology81
- Hematology78
- Rheumatology70
- Nephrology62
- Complementary and alternative medicine58
- Reproductive Medicine53
- Pharmacology49
- Emergency Medicine44
- Geriatrics and Gerontology38
- Otorhinolaryngology32
- Rehabilitation31
- Pathology and Forensic Medicine29
- Hepatology28
- Immunology and Allergy25
- Critical Care and Intensive Care Medicine24
- Genetics19
- Anesthesiology and Pain Medicine14
- Urology13
- Health Informatics10
- Gastroenterology6
- Internal Medicine6
- Family Practice2
- Transplantation2
- Anatomy0
- Biochemistry0
- Microbiology0
242 ranked journals
Filters
Rank is the position by OJR within the list on screen; 1 is the highest. The small range under it is the likely rank range: in 95% of 1,000 resamples of the journal’s papers, it ranked inside that range. Journals whose ranges overlap are not clearly different. | OJR is field-normalized 3-year citation impact: 1.00 is the world average for papers of the same subfield, year and type, so values compare across fields. The badge is the journal’s quartile in this list. | Citations per paper over a two-year window, counted from OpenAlex. It is not field-normalized, so compare it only between journals of the same field. ▲ or ▼ is the change from 2024. This is OpenJournalRank’s own count, not Clarivate’s Journal Impact Factor. | Citable documents (articles, reviews and conference papers) published in 2022–2024, the window the 2025 OJR is computed on. A journal needs at least 30 to be ranked. | Share of the journal’s 2022–2024 papers that are free to read in any open-access form. The green OA tag next to a title marks a fully open-access journal. | List price of the article processing charge in US dollars. “$0 listed” means the listed price is zero; a dash means no price is listed. | The line is the journal’s OJR from 2016 to 2025. A label compares the 2022→2025 change with the median change of the journal’s field or domain. Rising needs a relative change of +10% or more that is at least 2 standard errors above zero; Falling needs -9.1% or less (rounded), at least 2 standard errors below zero. Sorting uses that relative change. | Compare |
|---|---|---|---|---|---|---|---|
Rank 1; likely between #1 and #1 of 242CA A Cancer Journal for CliniciansOAWiley · United States | 116.27Q1 | 505.84 229.09 up from 2024 | 78 | 100% | $4,330 | ||
Rank 2; likely between #2 and #3 of 242Nature MedicineNature Portfolio · United States | 10.80Q1 | 33.21 0.42 up from 2024 | 1,446 | 55% | $12,690 | ||
Rank 3; likely between #2 and #5 of 242Journal of Hematology & OncologyOABioMed Central · United Kingdom | 9.48Q1 | 32.16 1.95 up from 2024 | 397 | 100% | $4,990 | Rising vs field, 2022–25 | |
Rank 4; likely between #2 and #5 of 242Cancer CellCell Press · Netherlands | 8.99Q1 | 38.39 10.90 up from 2024 | 541 | 57% | $10,400 | Rising vs field, 2022–25 | |
Rank 5; likely between #4 and #8 of 242Nature Reviews Clinical OncologyNature Portfolio · United Kingdom | 7.20Q1 | 36.39 4.12 up from 2024 | 368 | 12% | — | Rising vs field, 2022–25 | |
Rank 6; likely between #5 and #8 of 242Journal of Clinical OncologyLippincott Williams & Wilkins · United States | 7.00Q1 | 19.67 0.55 down from 2024 | 1,511 | 47% | — | ||
Rank 7; likely between #6 and #9 of 242The Lancet OncologyElsevier BV · United Kingdom | 6.16Q1 | 18.11 0.35 up from 2024 | 865 | 23% | $7,280 | ||
Rank 8; likely between #5 and #12 of 242Cancer DiscoveryAmerican Association for Cancer Research · United States | 5.80Q1 | 16.92 6.58 down from 2024 | 543 | 30% | — | ||
Rank 9; likely between #2 and #37 of 242Journal of the National Cancer CenterOAElsevier BV · China | 5.06Q1 | 18.92 10.03 up from 2024 | 129 | 100% | $2,160 | ||
Rank 10; likely between #8 and #13 of 242Journal of the National Comprehensive Cancer NetworkNational Comprehensive Cancer | 4.88Q1 | 13.42 0.76 down from 2024 | 561 | 20% | — | ||
Rank 11; likely between #8 and #12 of 242Nature CancerNature Portfolio · United States | 4.84Q1 | 16.64 2.22 down from 2024 | 468 | 41% | $12,690 | Rising vs field, 2022–25 | |
Rank 12; likely between #8 and #12 of 242Seminars in Cancer BiologyElsevier BV · United States | 4.77Q1 | 18.57 1.72 up from 2024 | 295 | 30% | $6,060 | Rising vs field, 2022–25 | |
Rank 13; likely between #11 and #15 of 242Annals of OncologyElsevier BV · Netherlands | 3.79Q1 | 11.14 1.68 up from 2024 | 1,055 | 74% | $5,080 | ||
Rank 14; likely between #13 and #16 of 242Cell Reports MedicineOAElsevier BV · United States | 3.25Q1 | 11.81 2.77 up from 2024 | 1,054 | 100% | $5,620 | ||
Rank 15; likely between #13 and #19 of 242JAMA OncologyAmerican Medical Association · United States | 3.15Q1 | 9.97 1.27 up from 2024 | 1,059 | 46% | — | ||
Rank 16; likely between #13 and #20 of 242American Society of Clinical Oncology Educational BookAmerican Society of Clinical Oncology · United States | 3.04Q1 | 9.53 0.03 up from 2024 | 226 | 56% | — | Rising vs field, 2022–25 | |
Rank 17; likely between #15 and #20 of 242Journal for ImmunoTherapy of CancerOABMJ · United Kingdom | 2.90Q1 | 10.92 0.37 up from 2024 | 1,393 | 100% | $2,490 | ||
Rank 18; likely between #14 and #21 of 242npj Precision OncologyOANature Portfolio · United Kingdom | 2.86Q1 | 10.43 1.55 up from 2024 | 509 | 100% | $4,090 | ||
Rank 19; likely between #15 and #20 of 242Clinical Cancer ResearchAmerican Association for Cancer Research · United States | 2.85Q1 | 8.83no change | 1,610 | 13% | — | ||
Rank 20; likely between #15 and #22 of 242Cancer Treatment ReviewsElsevier BV · United Kingdom | 2.74Q1 | 10.77 0.79 down from 2024 | 307 | 60% | $4,910 | ||
Rank 21; likely between #16 and #30 of 242npj Breast CancerOANature Portfolio · United States | 2.36Q1 | 8.54 0.36 up from 2024 | 320 | 100% | $3,790 | Rising vs field, 2022–25 | |
Rank 22; likely between #19 and #28 of 242MedElsevier BV · United States | 2.34Q1 | 7.69 1.39 up from 2024 | 379 | 48% | $9,350 | ||
Rank 23; likely between #20 and #27 of 242JNCI Journal of the National Cancer InstituteOxford University Press · United States | 2.33Q1 | 6.84 0.15 up from 2024 | 622 | 66% | $5,436 | ||
Rank 24; likely between #21 and #28 of 242ESMO OpenOAElsevier BV · Netherlands | 2.21Q1 | 7.88 1.09 up from 2024 | 740 | 100% | $3,910 | ||
Rank 25; likely between #20 and #30 of 242European Journal of EpidemiologySpringer Science+Business Media · Italy | 2.21Q1 | 6.29 0.14 down from 2024 | 336 | 77% | $3,690 | Falling vs field, 2022–25 | |
Rank 26; likely between #22 and #28 of 242British Journal of CancerSpringer Nature · United Kingdom | 2.18Q1 | 7.71 0.63 up from 2024 | 1,180 | 98% | $5,190 | ||
Rank 27; likely between #23 and #34 of 242Current Treatment Options in OncologySpringer Science+Business Media · United States | 2.02Q1 | 6.11 0.62 up from 2024 | 335 | 29% | $4,890 | ||
Rank 28; likely between #22 and #39 of 242Cancer Biology and MedicineOAChinese Anti-Cancer Association · China | 1.94Q1 | 6.74 0.82 up from 2024 | 207 | 100% | $1,500 | Rising vs field, 2022–25 | |
Rank 29; likely between #24 and #36 of 242Current Oncology ReportsSpringer Science+Business Media · United States | 1.93Q1 | 5.90 0.17 up from 2024 | 444 | 49% | $5,090 | ||
Rank 30; likely between #27 and #35 of 242European Journal of CancerElsevier BV · United Kingdom | 1.88Q1 | 6.95 0.59 up from 2024 | 1,228 | 44% | $4,270 | ||
Rank 31; likely between #27 and #42 of 242Trends in cancerElsevier BV · United States | 1.81Q1 | 12.98 2.25 up from 2024 | 349 | 46% | $7,030 | Rising vs field, 2022–25 | |
Rank 32; likely between #27 and #39 of 242Cancer Immunology ResearchAmerican Association for Cancer Research · United States | 1.81Q1 | 6.49 0.62 down from 2024 | 388 | 18% | — | Falling vs field, 2022–25 | |
Rank 33; likely between #30 and #44 of 242Clinical Pharmacology & TherapeuticsWiley · United States | 1.69Q1 | 4.51 0.92 down from 2024 | 861 | 71% | $4,410 | ||
Rank 34; likely between #30 and #45 of 242Breast Cancer ResearchOABioMed Central · United Kingdom | 1.68Q1 | 6.37 0.19 up from 2024 | 428 | 100% | $4,190 | ||
Rank 35; likely between #31 and #48 of 242Critical Reviews in Oncology/HematologyElsevier BV · Netherlands | 1.62Q1 | 6.65 0.57 up from 2024 | 655 | 32% | $4,190 | Rising vs field, 2022–25 | |
Rank 36; likely between #33 and #47 of 242OncoImmunologyOALandes Bioscience · United States | 1.61Q1 | 5.78 0.23 down from 2024 | 416 | 100% | $2,913 | ||
Rank 37; likely between #27 and #64 of 242Oncology ReviewsOAPAGEPress (Italy) · Switzerland | 1.60Q1 | 4.46 1.59 down from 2024 | 55 | 100% | $2,353 | ||
Rank 38; likely between #33 and #48 of 242CancerWiley · United States | 1.60Q1 | 4.58 0.26 up from 2024 | 1,411 | 69% | $4,790 | ||
Rank 39; likely between #28 and #58 of 242ImmunoTargets and TherapyOADove Medical Press · New Zealand | 1.58Q1 | 4.33 0.67 down from 2024 | 76 | 100% | $2,320 | ||
Rank 40; likely between #32 and #50 of 242International Journal of CancerWiley · United States | 1.57Q1 | 4.81 0.14 down from 2024 | 1,214 | 71% | $5,030 | ||
Rank 41; likely between #29 and #58 of 242Chinese Journal of Cancer ResearchOAAME Publishing Company · China | 1.55Q1 | 5.78 1.17 up from 2024 | 143 | 100% | — | ||
Rank 42; likely between #35 and #49 of 242Molecular Cancer TherapeuticsAmerican Association for Cancer Research · United States | 1.55Q1 | 5.69 0.87 up from 2024 | 438 | 16% | — | ||
Rank 43; likely between #23 and #82 of 242Cancer Pathogenesis and TherapyOAElsevier BV | 1.54Q1 | 5.26 2.71 up from 2024 | 114 | 100% | $1,100 | ||
Rank 44; likely between #33 and #53 of 242Cancer Drug ResistanceOAUnited States | 1.53Q1 | 6.09 0.85 up from 2024 | 180 | 100% | — | Rising vs field, 2022–25 | |
Rank 45; likely between #38 and #51 of 242The OncologistOAAlphaMed Press · United Kingdom | 1.49Q1 | 4.65 0.23 up from 2024 | 981 | 100% | $3,852 | ||
Rank 46; likely between #21 and #103 of 242BMJ OncologyOABMJ | 1.49Q1 | 4.67 0.37 up from 2024 | 104 | 100% | — | ||
Rank 47; likely between #38 and #51 of 242Cancer Immunology ImmunotherapyOASpringer Science+Business Media · Germany | 1.49Q1 | 5.85 0.42 up from 2024 | 718 | 100% | $4,590 | ||
Rank 48; likely between #30 and #67 of 242JNCI MonographsOxford University Press · United Kingdom | 1.49Q1 | 4.17 1.42 up from 2024 | 98 | 85% | — | ||
Rank 49; likely between #44 and #51 of 242CancersOAMultidisciplinary Digital Publishing Institute · Switzerland | 1.44Q1 | 5.15 0.25 up from 2024 | 16,172 | 100% | $3,499 | ||
Rank 50; likely between #31 and #77 of 242Medicine AdvancesOAWiley | 1.43Q1 | 5.18 4.49 up from 2024 | 71 | 100% | $0 listed |
20 Oncology journals are labelled rising: their OJR moved up between 2022 and 2025 clearly faster than the median journal of their field or domain.
A journal is rising when its OJR grew from 2022 to 2025 faster than the median journal of its field (or domain, when the field is small), by two tests: the relative change is +10% or more, and it is at least 2 standard errors above zero. So the range of the change at 2 standard errors stays above zero, though not necessarily above +10%.
The bar is that range on a ratio scale; the shaded band, -9.1% to +10%, holds changes too small for a label. The list is ordered by the low end of the range, so the surest rises come first.
- 1Annals of Hepato-Biliary-Pancreatic SurgeryOASouth Korea+66% vs groupOJR 0.35 → 0.54range +29% to +113%
- 2Seminars in Cancer BiologyElsevier BV · United States+53% vs groupOJR 3.34 → 4.77range +26% to +85%
- 3Journal of Hematology & OncologyOABioMed Central · United Kingdom+52% vs groupOJR 6.68 → 9.48range +25% to +84%
- 4Nature Reviews Clinical OncologyNature Portfolio · United Kingdom+60% vs groupOJR 4.80 → 7.20range +23% to +109%
- 5Trends in cancerElsevier BV · United States+47% vs groupOJR 1.31 → 1.81range +20% to +81%
- 6Cancer CellCell Press · Netherlands+48% vs groupOJR 6.49 → 8.99range +18% to +86%
- 7Journal of Cancer PolicyElsevier BV · Netherlands+67% vs groupOJR 0.43 → 0.68range +17% to +137%
- 8Molecular and Clinical OncologyOASpandidos Publishing · United Kingdom+41% vs groupOJR 0.48 → 0.64range +16% to +73%
- 9Cancer Drug ResistanceOAUnited States+82% vs groupOJR 0.90 → 1.53range +13% to +194%
- 10Nature CancerNature Portfolio · United States+36% vs groupOJR 3.80 → 4.84range +10% to +68%
- 11Cancer NursingLippincott Williams & Wilkins · United States+34% vs groupOJR 0.71 → 0.89range +9.7% to +64%
- 12Critical Reviews in Oncology/HematologyElsevier BV · Netherlands+28% vs groupOJR 1.35 → 1.62range +8.0% to +51%
- 13American Society of Clinical Oncology Educational BookAmerican Society of Clinical Oncology · United States+37% vs groupOJR 2.37 → 3.04range +7.1% to +75%
- 14Cancer Biology and MedicineOAChinese Anti-Cancer Association · China+36% vs groupOJR 1.52 → 1.94range +6.3% to +75%
- 15Inorganica Chimica ActaElsevier BV · Netherlands+17% vs groupOJR 0.58 → 0.63range +6.1% to +30%
- 16Psycho-OncologyWiley · United Kingdom+21% vs groupOJR 1.10 → 1.25range +4.6% to +39%
- 17Canadian Oncology Nursing JournalOAPappin Communications · Canada+71% vs groupOJR 0.24 → 0.38range +2.2% to +187%
- 18npj Breast CancerOANature Portfolio · United States+39% vs groupOJR 1.82 → 2.36range +2.2% to +88%
- 19JCO Oncology PracticeLippincott Williams & Wilkins · United States+20% vs groupOJR 1.15 → 1.30range +1.4% to +42%
- 20Journal of Breast ImagingOxford University Press · United States+37% vs groupOJR 0.36 → 0.46range +1.3% to +84%
No-label zone, -9.1% to +10%Group median changeBar scale -68% to +211% (ratio scale)
25 Oncology journals are labelled falling: their OJR moved between 2022 and 2025 clearly behind the median journal of their field or domain.
A journal is falling when its OJR changed from 2022 to 2025 by less than the median journal of its field (or domain, when the field is small), by two tests: the relative change is -9.1% or less (rounded), and it is at least 2 standard errors below zero. So the range of the change at 2 standard errors stays below zero, though not necessarily below -9.1%.
The bar is that range on a ratio scale; the shaded band, -9.1% to +10%, holds changes too small for a label. The list is ordered by the high end of the range, so the surest falls come first.
- 1OncologyKarger Publishers · Switzerland-43% vs groupOJR 0.96 → 0.51range -55% to -27%
- 2Oncology Research and TreatmentKarger Publishers · Switzerland-43% vs groupOJR 0.77 → 0.41range -57% to -25%
- 3Frontiers in OncologyOAFrontiers Media · Switzerland-22% vs groupOJR 1.45 → 1.06range -25% to -18%
- 4Asian Pacific Journal of Cancer CareOAIran-42% vs groupOJR 0.33 → 0.18range -60% to -15%
- 5Anticancer ResearchInternational Institute of Anticancer Research (IIAR) Conferences 1997. Athens, Greece. Abstracts · Greece-21% vs groupOJR 0.64 → 0.47range -28% to -14%
- 6International Journal of Cancer ManagementOAIran-42% vs groupOJR 0.26 → 0.14range -61% to -12%
- 7Cancer Immunology ResearchAmerican Association for Cancer Research · United States-25% vs groupOJR 2.56 → 1.81range -36% to -11%
- 8JCO Clinical Cancer InformaticsLippincott Williams & Wilkins · United States-34% vs groupOJR 1.43 → 0.89range -52% to -9.8%
- 9Journal of Gastrointestinal OncologyOAAME Publishing Company · Hong Kong SAR China-21% vs groupOJR 0.77 → 0.57range -32% to -9.4%
- 10European Journal of EpidemiologySpringer Science+Business Media · Italy-36% vs groupOJR 3.67 → 2.21range -55% to -8.7%
- 11Acta OncologicaOATaylor & Francis · United Kingdom-20% vs groupOJR 0.91 → 0.68range -31% to -8.2%
- 12Journal of Surgical OncologyWiley · United States-17% vs groupOJR 0.86 → 0.67range -26% to -6.3%
- 13In VivoOAStanford University Highwire Press · Greece-20% vs groupOJR 0.77 → 0.58range -32% to -5.6%
- 14Seminars in Oncology NursingElsevier BV · United States-38% vs groupOJR 1.66 → 0.96range -60% to -5.1%
- 15Cancer MedicineOAWiley · United Kingdom-12% vs groupOJR 1.33 → 1.10range -19% to -4.6%
- 16Current Opinion in OncologyLippincott Williams & Wilkins · United Kingdom-26% vs groupOJR 1.22 → 0.84range -43% to -4.2%
- 17Supportive Care in CancerSpringer Science+Business Media · Germany-11% vs groupOJR 1.03 → 0.86range -18% to -4.1%
- 18Expert Review of Anticancer TherapyTaylor & Francis · United Kingdom-21% vs groupOJR 0.99 → 0.73range -36% to -3.4%
- 19Journal of Inorganic BiochemistryElsevier BV · United States-15% vs groupOJR 0.95 → 0.75range -27% to -1.8%
- 20Clinical journal of oncology nursingOncology Nursing Society · United States-27% vs groupOJR 0.42 → 0.29range -46% to -1.5%
No-label zone, -9.1% to +10%Group median changeBar scale -63% to +172% (ratio scale)
Subfields of Medicine, with Oncology highlighted.
- Surgery945
- Pulmonary and Respiratory Medicine352
- Public Health, Environmental and Occupational Health311
- Cardiology and Cardiovascular Medicine287
- Infectious Diseases258
- Oncology242
- Epidemiology178
- Neurology168
- Radiology, Nuclear Medicine and Imaging160
- Physiology154
- Endocrinology, Diabetes and Metabolism152
- Psychiatry and Mental health139
- Orthopedics and Sports Medicine121
- Ophthalmology96
- Pediatrics, Perinatology and Child Health95
- Dermatology89
- Obstetrics and Gynecology81
- Hematology78
- Rheumatology70
- Nephrology62
- Complementary and alternative medicine58
- Reproductive Medicine53
- Pharmacology49
- Emergency Medicine44
- Geriatrics and Gerontology38
- Otorhinolaryngology32
- Rehabilitation31
- Pathology and Forensic Medicine29
- Hepatology28
- Immunology and Allergy25
- Critical Care and Intensive Care Medicine24
- Genetics19
- Anesthesiology and Pain Medicine14
- Urology13
- Health Informatics10
- Gastroenterology6
- Internal Medicine6
- Family Practice2
- Transplantation2
- Anatomy0
- Biochemistry0
- Microbiology0
Journals
The endpoints below each rank show its likely range. How rank ranges are calculated
Citations made in 2025. Corpus-wide, 84.3% of core-journal articles and reviews published that year have at least one matched reference; the share varies by journal and field.
55 additional Oncology journals with metrics are unranked under this release’s eligibility rules: a journal needs at least 30 citable documents in 2022–2024, at least 80% of them with a subfield, and a positive world-average expectation. Ranks are within the whole category; filters hide rows without re-ranking. OJR excludes self-citations.
At a glance
Indicator year: 2025. Publication window: 2022–2024. How these summaries are calculated
- Ranked journals
- 242
- Window papers (baseline)
- 160,807 +2.5% from indicator year 2022
- Median OJR
- 0.748 -2.6% from indicator year 2022
- Rising journals (2025)
- 20
Window papers are the baseline paper population: citable papers (articles, reviews and conference papers) from 2022–2024 in all journals of the world-average baseline, including non-core journals, counted by each paper’s own subfield. They are not the papers of the ranked journals alone.
| Measure | Year series | 2000 | 2001 | 2002 | 2003 | 2004 | 2005 | 2006 | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ranked journals | 82 | 88 | 96 | 103 | 109 | 120 | 120 | 126 | 127 | 134 | 141 | 150 | 153 | 170 | 179 | 188 | 198 | 213 | 224 | 234 | 238 | 239 | 245 | 245 | 243 | 242 | |
| Window papers (baseline) | 37,821 | 41,430 | 44,340 | 47,392 | 49,058 | 53,111 | 57,002 | 62,106 | 66,087 | 71,283 | 77,009 | 82,075 | 86,189 | 88,804 | 93,912 | 98,660 | 102,921 | 105,891 | 109,984 | 115,044 | 121,890 | 139,666 | 156,942 | 167,602 | 163,907 | 160,807 | |
| Median OJR | 0.55 | 0.62 | 0.70 | 0.799 | 0.805 | 0.831 | 0.85 | 0.90 | 0.94 | 0.93 | 1.010 | 0.95 | 1.006 | 0.974 | 0.972 | 0.967 | 0.832 | 0.84 | 0.82 | 0.79 | 0.829 | 0.830 | 0.77 | 0.750 | 0.73 | 0.748 |
How to read these rankings
- OJR, the OpenJournalRank Indicator
- A field-normalized 3-year citation impact, computed from OpenAlex with the NCI3 method. It divides the citations a journal’s papers received by the world average for papers of the same subfield, year and type, so 1.00 is the world average and 2.00 means twice as many citations as expected. Because it is normalized, it can be compared across fields. Read the methodology
- Quartiles
- Q1 to Q4 split the ranked journals of the list you are viewing into four equal groups by OJR. A journal’s quartile depends on the list: the same journal can be Q1 in its subfield and Q2 among all journals.
- Impact factor (2-year)
- Citations per paper over a two-year window, counted from OpenAlex. It is easy to compare with familiar impact factors but is not field-normalized, so compare it only within a field. It is not Clarivate’s Journal Impact Factor. Why it differs from the Journal Impact Factor
- Rank ranges
- Each rank in the latest year carries a likely range from 1,000 resamples of the journal’s papers. Where two journals’ ranges overlap, the data cannot tell them apart, so treat neighbouring ranks as ties.